

Supplementary material

Okauchi S, Shiozawa T, Miyazaki K, et al. Association between peripheral eosinophils and clinical outcomes in patients with non–small cell lung cancer treated with immune checkpoint inhibitors. *Pol Arch Intern Med.* 2021; 131: 152-160. doi:10.20452/pamw.15776

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.




Figure S1. Change between the percentage of eosinophils at the initiation of immune checkpoint inhibitor therapy and the maximum percentage of eosinophils after initiation of immune checkpoint inhibitor therapy in each non-small cell lung cancer patient with controlled disease (A) and in patients with progressive disease (B).

